Scholar Rock Holding buy Piper Sandler
Start price
26.03.24
/
50%
€14.70
Target price
26.03.25
€25.79
Performance (%)
-4.08%
Price
02.05.24
€14.10
Summary
This prediction is currently active. With a performance of -4.08%, the BUY prediction by Piper_Sandler is trending in the wrong direction. This prediction currently runs until 26.03.25. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionScholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Scholar Rock Holding | 8.462% | 8.462% |
| iShares Core DAX® | 0.000% | -2.064% |
| iShares Nasdaq 100 | 0.626% | -2.884% |
| iShares Nikkei 225® | 1.568% | -5.892% |
| iShares S&P 500 | 0.334% | -2.281% |
Comments by Piper_Sandler for this prediction
In the thread Scholar Rock Holding diskutieren
Scholar Rock Holding Co. (NASDAQ: SRRK) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat
Stopped prediction by Piper_Sandler for Scholar Rock Holding
Scholar Rock Holding
Start price
Target price
Perf. (%)
€7.70
03.04.23
03.04.23
€23.86
03.04.24
03.04.24
84.42%
04.04.24
04.04.24
